S&P 500   5,098.15 (+0.04%)
DOW   38,932.87 (-0.16%)
QQQ   440.83 (+0.42%)
AAPL   180.18 (-0.32%)
MSFT   413.57 (-0.02%)
META   495.66 (+1.13%)
GOOGL   138.33 (-0.09%)
AMZN   176.59 (-0.10%)
TSLA   200.32 (-0.77%)
NVDA   802.67 (+1.46%)
NIO   5.78 (+0.52%)
AMD   199.45 (+3.59%)
BABA   74.72 (+0.93%)
T   16.83 (-0.59%)
F   12.42 (-0.16%)
MU   93.59 (+3.29%)
CGC   3.28 (-0.30%)
GE   157.18 (+0.18%)
DIS   111.71 (+0.12%)
AMC   4.33 (+0.23%)
PFE   26.84 (+1.05%)
PYPL   60.55 (+0.35%)
XOM   105.95 (+1.37%)
S&P 500   5,098.15 (+0.04%)
DOW   38,932.87 (-0.16%)
QQQ   440.83 (+0.42%)
AAPL   180.18 (-0.32%)
MSFT   413.57 (-0.02%)
META   495.66 (+1.13%)
GOOGL   138.33 (-0.09%)
AMZN   176.59 (-0.10%)
TSLA   200.32 (-0.77%)
NVDA   802.67 (+1.46%)
NIO   5.78 (+0.52%)
AMD   199.45 (+3.59%)
BABA   74.72 (+0.93%)
T   16.83 (-0.59%)
F   12.42 (-0.16%)
MU   93.59 (+3.29%)
CGC   3.28 (-0.30%)
GE   157.18 (+0.18%)
DIS   111.71 (+0.12%)
AMC   4.33 (+0.23%)
PFE   26.84 (+1.05%)
PYPL   60.55 (+0.35%)
XOM   105.95 (+1.37%)
S&P 500   5,098.15 (+0.04%)
DOW   38,932.87 (-0.16%)
QQQ   440.83 (+0.42%)
AAPL   180.18 (-0.32%)
MSFT   413.57 (-0.02%)
META   495.66 (+1.13%)
GOOGL   138.33 (-0.09%)
AMZN   176.59 (-0.10%)
TSLA   200.32 (-0.77%)
NVDA   802.67 (+1.46%)
NIO   5.78 (+0.52%)
AMD   199.45 (+3.59%)
BABA   74.72 (+0.93%)
T   16.83 (-0.59%)
F   12.42 (-0.16%)
MU   93.59 (+3.29%)
CGC   3.28 (-0.30%)
GE   157.18 (+0.18%)
DIS   111.71 (+0.12%)
AMC   4.33 (+0.23%)
PFE   26.84 (+1.05%)
PYPL   60.55 (+0.35%)
XOM   105.95 (+1.37%)
S&P 500   5,098.15 (+0.04%)
DOW   38,932.87 (-0.16%)
QQQ   440.83 (+0.42%)
AAPL   180.18 (-0.32%)
MSFT   413.57 (-0.02%)
META   495.66 (+1.13%)
GOOGL   138.33 (-0.09%)
AMZN   176.59 (-0.10%)
TSLA   200.32 (-0.77%)
NVDA   802.67 (+1.46%)
NIO   5.78 (+0.52%)
AMD   199.45 (+3.59%)
BABA   74.72 (+0.93%)
T   16.83 (-0.59%)
F   12.42 (-0.16%)
MU   93.59 (+3.29%)
CGC   3.28 (-0.30%)
GE   157.18 (+0.18%)
DIS   111.71 (+0.12%)
AMC   4.33 (+0.23%)
PFE   26.84 (+1.05%)
PYPL   60.55 (+0.35%)
XOM   105.95 (+1.37%)

Harrow Health (HROW) Stock Price, News & Analysis

$10.82
-0.12 (-1.10%)
(As of 02/29/2024 ET)
Today's Range
$10.62
$11.16
50-Day Range
$9.30
$11.95
52-Week Range
$7.60
$28.25
Volume
221,374 shs
Average Volume
388,838 shs
Market Capitalization
$380.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.80

Harrow Health MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
258.4% Upside
$38.80 Price Target
Short Interest
Bearish
14.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.85mentions of Harrow Health in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.43) to $0.40 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.12 out of 5 stars

Medical Sector

635th out of 957 stocks

Pharmaceutical Preparations Industry

299th out of 437 stocks


HROW stock logo

About Harrow Health Stock (NASDAQ:HROW)

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

HROW Stock Price History

HROW Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
HROWM Harrow Health, Inc. NT CAL 27
Harrow to Present at Two Investor Conferences in November
Harrow Recent Insider Activity
Why Is Eyecare-Focused Harrow Health Stock Trading Lower Today?
Harrow Announces Third Quarter 2023 Financial Results
Harrow Inc HROW
Implications Of Harrow's Short-Term Guidance
Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.
Harrow Health's 5-Year Guidance
See More Headlines
Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
3/01/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:HROW
Employees
182
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.80
High Stock Price Target
$45.00
Low Stock Price Target
$34.40
Potential Upside/Downside
+258.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-14,090,000.00
Pretax Margin
-11.36%

Debt

Sales & Book Value

Annual Sales
$88.60 million
Cash Flow
$0.22 per share
Book Value
$1.01 per share

Miscellaneous

Free Float
30,342,000
Market Cap
$380.17 million
Optionable
Optionable
Beta
0.44
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Mark L. Baum J.D. (Age 49)
    CEO & Chairman
    Comp: $1.07M
  • Mr. Andrew R. Boll C.F.A. (Age 40)
    C.M.A., CFA, CMA, CFO & Corp. Sec.
    Comp: $716.73k
  • Dr. Robert J. Kammer D.D.S. (Age 73)
    Special Advisor
    Comp: $91.88k
  • Mr. John P. Saharek MBA (Age 62)
    Chief Commercial Officer
    Comp: $621.92k
  • Jamie Webb
    Director of Communications & Investor Relations
  • Dr. Dennis E Saadeh Pharm.D.
    Chief of Formulation Strategy
  • Mr. Andrew Livingston
    Chief Innovation Officer
  • Ms. Kim Barratt
    Chief Talent Officer














HROW Stock Analysis - Frequently Asked Questions

Should I buy or sell Harrow Health stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HROW shares.
View HROW analyst ratings
or view top-rated stocks.

What is Harrow Health's stock price target for 2024?

2 analysts have issued 1-year price objectives for Harrow Health's shares. Their HROW share price targets range from $34.40 to $45.00. On average, they anticipate the company's stock price to reach $38.80 in the next year. This suggests a possible upside of 258.4% from the stock's current price.
View analysts price targets for HROW
or view top-rated stocks among Wall Street analysts.

How have HROW shares performed in 2024?

Harrow Health's stock was trading at $11.20 at the beginning of 2024. Since then, HROW stock has decreased by 3.3% and is now trading at $10.8250.
View the best growth stocks for 2024 here
.

When is Harrow Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our HROW earnings forecast
.

How were Harrow Health's earnings last quarter?

Harrow Health, Inc. (NASDAQ:HROW) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.03 by $0.12. The firm earned $34.27 million during the quarter, compared to analyst estimates of $37.58 million. Harrow Health had a negative net margin of 12.44% and a negative trailing twelve-month return on equity of 6.55%. The company's revenue for the quarter was up 50.1% on a year-over-year basis. During the same period last year, the firm earned ($0.06) earnings per share.

What ETFs hold Harrow Health's stock?

ETFs with the largest weight of Harrow Health (NASDAQ:HROW) stock in their portfolio include Jacob Forward ETF (JFWD) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What other stocks do shareholders of Harrow Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).

Who are Harrow Health's major shareholders?

Harrow Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Opaleye Management Inc. (10.88%), Vanguard Group Inc. (5.15%), Braidwell LP (4.27%), Ophir Asset Management Pty Ltd (1.56%), Stifel Financial Corp (1.23%) and Northern Trust Corp (0.90%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Martin A Makary, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom.
View institutional ownership trends
.

How do I buy shares of Harrow Health?

Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HROW) was last updated on 3/1/2024 by MarketBeat.com Staff